Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE".
Vyome Holdings Inc HIND
$2.04
▼ -0.97%
($-0.02)
🎈 Low Float
Open
$2.07
Prev Close
$2.06
Day Range
$2.01 – $2.08
52W Range
$1.75 – $6.56
Market Cap
$14.32M
Beta
1.60
EPS (TTM)
$-3.51
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-10-06 |
| Shares Out. | 7,020,000 |
| Website | reshapelifesciences.com/obalon/ ↗ |
| Phone | 13026365400 |
| Employees | 18 |
| Revenue | $26,955 |
| Gross Profit | $11,658 |
| Net Income | -$719,683 |
| Free Cash Flow | $524,471 |
| Total Assets | $9.2M |
| Total Liabilities | $1.9M |
| Equity | $7.3M |
About Vyome Holdings Inc
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Vyome Holdings Inc is a publicly traded company under the ticker symbol HIND on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)